Atlas FDA

SYNERGY SHIELD Monorail Everolimus-Eluting Platinum Chromium Coronary Stent System, YNERGY MEGATRON Monorail Everolimu

FDA premarket approval P150003/S102 · decided 2024-10-01

Approval details

PMA number
P150003
Supplement
S102
Supplement type
Real-Time Process
Supplement reason
Change Design/Components/Specifications/Material
Trade name
SYNERGY SHIELD Monorail Everolimus-Eluting Platinum Chromium Coronary Stent System, YNERGY MEGATRON Monorail Everolimu
Generic name
Coronary drug-eluting stent
Applicant
Boston Scientific Corporation
Date received
2024-07-01
Decision date
2024-10-01
Days to decision
92 days
Decision code
APPR
Product code
NIQ
Advisory committee
Cardiovascular
Expedited review
No
Location
Maple Grove, MN
Statement
the removal of the polytetrafluoroethylene (PTFE) coating on the delivery system hypotube and the addition of black ink proximal markers

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
TheraSphere 360™ Y-90 Management Platform (K262462)Boston Scientific Corporation2026-07-24
FARADRIVE™ Steerable Sheath (M004PF21M402) (K262165)Boston Scientific Corporation2026-07-24
OBSIDIO Conformable Embolic (K261488)Boston Scientific Corporation2026-07-24
WallFlex Esophageal Stent System;Agile Esophageal Over-the-Wire (OTW) Stent System (K261978)Boston Scientific Corporation2026-07-10
RIVOS™ EUS Access Device (M00553900) (K260428)Boston Scientific Corporation2026-06-17
MOSES Raydar™ (K260100)Boston Scientific Corporation2026-05-18
TruSelect™ 2.6 Microcatheter (K260771)Boston Scientific Corporation2026-05-15
Asurys Fluid Management System (K251273)Boston Scientific Corporation2026-03-27